Delcath Systems Inc
DCTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$591.7M
Close$
$1.07
93.7% downside
Current Fair Value
93.7% downsideOvervalued by 93.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $591.70 Million |
|---|---|
| Enterprise Value | $546.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.08 |
| Beta | 0.52 |
| Outstanding Shares | 35,891,915 |
Return
| Return on Equity | 0.44% |
|---|---|
| Return on Assets | 0.39% |
| Return on Invested Capital | 0.45% |
Valuation & Multiples
| P/E Ratio | 1558.18 |
|---|---|
| PEG | -144910.91 |
| Price to Sales | 16.94 |
| Price to Book Ratio | 5.65 |
| Enterprise Value to Revenue | 11 |
| Enterprise Value to EBIT | 970.95 |
| Enterprise Value to Net Income | 1027 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$26.25 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$26.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5806▼ 29.50% |
|---|---|
| Total Calls | 312,800▲ 14.49% |
| Total Puts | 181,600▼ 24.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 48.61%▲ 3.06% |
|---|---|
| Total Invested | $220.72M▲ 45.66% |
| Investors Holding | 1290% |
ESG Score
No data
About Delcath Systems Inc
CEO: Jennifer Simpson Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...